Summary
The literature was reviewed for cases of cutaneous pigmentation induced by rifampicin overdosage. 29 examples have been described, in which 2 general groups of individuals were observed. The first consisted of older individuals (average age 27.1 years) who attempted suicide. A prior history of suicide attempts, depression and substance abuse was a predominant factor in these patients. The second group included generally younger patients (average age 2.9 years) in whom misformulation of rifampicin preparations for treatment of Haemophilus influenzae Type B resulted in bright reddish-orange discoloration to the skin.
The time to clinical appearance of skin discoloration was approximately 2.2 hours after administration. Periorbital or facial oedema occurred in 72.4% of the patients, prurit is in 62.1% and either nausea, vomiting or diffuse abdominal tenderness in 51.7%. Limited laboratory data are available but these indicate that all patients had elevated levels of total bilirubin. Histological examination in selected individuals revealed rifampicin crystal deposits in the nasopharynx, gastrointestinal tract and lining of the aorta.
In adults, it appears that a dose of at least 14g of rifampicin is necessary before cardiovascular-pulmonary arrest occurs. Other than general supportive measures, very few methods are described in the literature for the treatment of acute intoxications with this drug.
A differential diagnosis of other causes of reddish-orange pigmentation is discussed, together with clinical information to differentiate these cases from toxic rifampicin ingestion.
Similar content being viewed by others
References
American Academy of Pediatrics. Report of the committee on infectious diseases, American Academy of Pediatrics, 20th ed., pp. 169–174, Dekker, Illinois, 1986
Bareford D, Cumberbatch M, Tovey LD. Plasma discoloration due to suntanning aids. Vox Sanguinis 46: 180–182, 1984
Bolan G, Laurie RE, Broome CV. Redman syndrome: inadvertent administration of an excessive dose of rifampicin to children in a day-care center. Pediatrics 77: 633–635, 1986
Broadwell RO, Broadwell SD, Comer PB. Suicide by rifampicin overdosage. Journal of the American Medical Association 240: 2283–2284, 1978
Centers for Disease Control. Prevention of secondary cases of Haemophilus influenzae Type B disease. Morbidity and Mortality Weekly Report 31: 672–680, 1982
DeSousa JS, Almedia V, Pinheiro B. Red child syndrome. Archives of Diseases in Children 62: 1181, 1987
Ducobu J, Dupont P, Laurent M, Bruart J. Acute isoniazid/ethambutol/rifampicin overdosage. Lancet 1: 632, 1982
Geiter LJ, O’Brien RJ. Conference on new approaches for tuberculosis preventive therapy. Journal of Infectious Diseases 156: 536–537, 1987
Granstein RD, Sober AJ. Drug and heavy metal induced hyperpigmentation. Journal of the American Academy of Dermatology 5: 1–18, 1981
Gross DJ, Dellinger RP. Red/orange person syndrome. Cutis 42: 175–177, 1988
Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs: a review. Clinical Pharmacokinetics 9: 511–544, 1984
Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs: a review. International Journal of Dermatology 24: 280–285, 1985
Holdiness MR. Rifampicin adverse cutaneous reactions. International Journal of Dermatology 25: 72–73, 1986
Holdiness MR. Neurological manifestations and toxicities of the antituberculosis drugs: a review. Medical Toxicology 2: 33–51, 1987a
Holdiness MR. Teratology of the antituberculosis drugs: a review. Early Human Development 15: 61–74, 1987b
Holdiness MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle 68: 301–309, 1987c
Holdiness MR. Clinical pharmacokinetics of clofazimine: a review. Clinical Pharmacokinetics 16: 74–85, 1989
Jack DB, Knepil J, McLay WDS, Fergie R. Fatal rifampicinethambutol overdosage. Lancet 1: 1107–1108, 1978
Konietzko N, Burkhardt H. Erfolgloser Suicidversuch mit Rifampicin. Pneumonologie 144: 82–85, 1971
Lacouture PG, Epstein MF, Mitchell AA. Vancomycin-associated shock and rash in the newborn infant. Journal of Pediatrics 111: 615–616, 1987
Maggi N, Furesz S, Pallanza G. Rifampicin desacetylation in the human organism. Arzneimittel-Forschung 19: 651–654, 1969
Meisel S, Brower R. Rifampicin: a suicidal dose. Annals of Internal Medicine 92: 262–263, 1980
Newton RW, Forrest ARW. Rifampicin overdosage —the redman syndrome. Scottish Medical Journal 20: 55–56, 1975
Odio C, Mohs E, Sklar FH, Nelson JD, McCracken GH. Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. American Journal of Diseases in Children 138: 17–19, 1984
Plomp TA, Battista HJ, Unterdorfer H, van Ditmarsch WC, Maes RAA. A case of fatal poisoning by rifampicin. Archives of Toxicology 48: 245–252, 1981
Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the redman syndrome: pharmacodynamics of histamine release. Journal of Infectious Diseases 157: 502–507, 1988
Rolston KVI, Hoy J. Man/woman achieves whole red personhood through vancomycin. Journal of the American Medical Association 255: 2445, 1986
Sharman IM. Hypercarotenaemia. British Medical Journal 290: 290–291, 1985
Sibbald RG, Schachter RK. The skin and diabetes mellitus. International Journal of Dermatology 23: 567–584, 1984
Sokol NJ, Lichenstein PK, Farrell MK. Quinacrine hydrochloride induced yellow discoloration of the skin in children. Pediatrics 69: 232–233, 1982
Southorn PA, Plevok DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clinic Proceedings 61: 721–724, 1986
Thestrup-Pedersen K, Halkier-Sorensen L, Sogaad H, Zachariae H. The redman syndrome: exfoliative dermatitis of unknown etiology —a description and follow up of 38 cases. Journal of the American Academy of Dermatology 18: 1307–1312, 1988
Wade TP, Mueller GL. Vancomycin and the redneck syndrome. Archives of Surgery 121: 859–860, 1986
Wong W, Bottorff MB, Heritage RW, Piecoro JJ, Rodgers GC. Acute rifampicin overdosage: a pharmacokinetic study and review of the literature. Journal of Pediatrics 104: 781–783, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holdiness, M.R. A Review of the Redman Syndrome and Rifampicin Overdosage. Med Toxicol Adverse Drug Exp 4, 444–451 (1989). https://doi.org/10.1007/BF03259925
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259925